32 / 68
ינואר 5102
- 32 -
מקורות
Biegon, A. (2004). Cannabinoids as Neuroprotective Agents in Traumatic Brain Injury. Current Pharmaceutical
1.
Design, 10, 2177-2183.
Bolla, K.I., Eldreth, D.A., Matochik, J.A. & Cadet, J.L. (2005). Neural substrate of faulty decision-making in
2.
abstinent marijuana users. Neuroimage, 26(2), 480-492.
Croxford, J.L. (2003). Therapeutic Potential of Cannabinoids in CNS Disease. CNS Drugs, 17 (3), 179–202.
3.
Dregan, A. & Gulliford, M.C. (2012). Is illicit drug use harmful to cognitive functioning in the mid-adult years? A
4.
cohort-based investigation. Am. J. Epidemiol. 175, 218-227.
D’Souza, D.C., Perry, E., MacDougall, L., Ammerman, Y. & Cooper, T. (2004). The psychotomimetic
5.
effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis.
Neuropsychopharmacology, 29 (1), 558-572.
Fernandez-Serrano, M.J., Perez-Garcia, M. & Verdejo-Garcia,A. (2011). What are the specific versus generalized
6.
effects of drugs of abuse on neuropsychological performance? Neurosci. Biobehav. Rev. 35, 377-406.
Gaoni, Y. & Mechoulam, R. (1964). Isolation, structure and partial synthesis of an active constituent of hashish.
7.
J. Am. Chem. Soc. 86, 1646-1647.
Galve-Roperh, I., Palazuelos, J., Aguado, T. & Guzman, M. (2009). The endocannabinoid system and the
8.
regulation of neural development: potential implications in psychiatric disorders. Eur. Arch. Psychiatry Clin.
Neurosci. 259, 371-382.
Hill, M.N., Carrier, E.J., McLaughlin, R.J., Morrish, A.C., Meier, S.E., et al. (2008). Regional alterations in the
9.
endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J.
Neurochem. 106, 2322-2336.
Hill, M.N., McLaughlin, R.J., Pan, B., Fitzgerald, M.L., Roberts, C.J., et al. (2011). Recruitment of prefrontal
10.
cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J.
Neurosci. 31, 10506-10515.
Lev-Ran, S., Roerecke, M., Le Foll, B., George, T.P., McKenzie, K. & Rehm, J. (2014). The association between
11.
cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychological
Medicine, 44, 797-810.
Maas, A.I.R., Murray, G., Henney, H., Kassem, N., Legrand, V., Mangelus, M., Muizelaar, J.P., Stocchetti, N.
12.
& Knoller, N. (2006). Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III
randomised, placebo-controlled, clinical trial. Lancet Neurol, 5, 38-45.
Mechoulam, R. & Parker, L.A. (2013). The Endocannabinoid System and the Brain. Annu. Rev. Psychol. 64,
13.
21-47.
Mechoulam, R., Parker, L.A. & Gallily, R. (2002). Cannabidiol: an overview of some pharmacological aspects.
14.
J. Clin. Pharmacol. 42, 11-19.
Oudin, M.J., Hobbs, C. & Doherty, P. (2011). DAGL-dependent endocannabinoid signalling: roles in axonal
15.
pathfinding, synaptic plasticity and adult neurogenesis. Eur. J. Neurosci. 34, 1634-1646.
Pertwee, R.G., Howlett, A.C., Abood, M.E., Alexander, S.P., Di Marzo, V., et al. (2010). Cannabinoid receptors
16.
and their ligands: beyond CB1 and CB2. Pharmacol. Rev. 62, 588-631.
Ranganathan, M. & D’Souza, D.C. (2006). The acute effects of cannabinoids on memory in humans: a review.
17.
Psychopharmacology (Berl.), 188 ,425-444.
Solowij, N., & Battisti, R. (2008). The chronic effects of cannabis on memory in humans: a review. Curr. Drug
18.
Abuse Rev. 1, 81-98.
Ware, M.A., Wang, T., Shapiro, S., Robinson, A., Ducruet, T., Huynh, T., Gamsa, A., Bennett, G.J. & Collet, J.P.
19.
(2010). Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ, 182 (14), 694-
701.